Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Standard BioTools
LAB
Standard BioTools
Academic Funding Cuts Will Challenge Performance Yet Yield Slight Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
08 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.55
20.6% undervalued
intrinsic discount
16 Aug
US$1.23
Loading
1Y
-30.5%
7D
-5.7%
Author's Valuation
US$1.6
20.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.6
20.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-165m
172m
2014
2017
2020
2023
2025
2026
2028
Revenue US$73.2m
Earnings US$9.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-19.06%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.25%
Calculation
US$9.38m
Earnings '28
x
83.42x
PE Ratio '28
=
US$782.14m
Market Cap '28
US$782.14m
Market Cap '28
/
409.96m
No. shares '28
=
US$1.91
Share Price '28
US$1.91
Share Price '28
Discounted to 2025 @ 7.25% p.a.
=
US$1.55
Fair Value '25
